A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Active:	Yes
Cancer Type:	Cervical Cancer Unknown Primary	NCT ID:	NCT06459180
Trial Phases:	Phase III	Protocol IDs:	2870-020 (primary) NCI-2024-09277 2023-508323-12 ENGOT-cx20 GOG-3101 jRCT2031240201 MK-2870-020 TroFuse-020 U1111-1298-0563
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06459180

Summary

This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3
portion. The safety run-in phase will be used to evaluate the efficacy and safety of
sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of
this study is to compare the efficacy and safety of sacituzumab tirumotecan versus
treatment of physician's choice as second-line treatment for participants with recurrent
or metastatic cervical cancer in the Phase 3 portion.

The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan
results in a superior overall survival compared to TPC in participants with high
trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.

Treatment Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org

Doctors:

Sarah Elizabeth Gill MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.